No difference in ischemic events or major bleeding were observed between the continuation of aspirin monotherapy versus no antiplatelet therapy in patients with a drug-eluting stent (DES) undergoing non- cardiac surgery, with a modest increase in minor bleeding, the ASSURE-DES trial reveals.